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Abstract
In single-arm phase II oncology trials, the most popular choice of design is Simon’s two-stage
design, which allows early stopping at one interim analysis. However, the expected trial sample
size can be reduced further by allowing curtailment. Curtailment is stopping when the final
go or no-go decision is certain, so-called non-stochastic curtailment, or very likely, known as
stochastic curtailment.
In the context of single-arm phase II oncology trials, stochastic curtailment has previously
been restricted to stopping in the second stage and/or stopping for a no-go decision only. We
introduce two designs that incorporate stochastic curtailment and allow stopping after every ob-
servation, for either a go or no-go decision. We obtain optimal stopping boundaries by searching
over a range of potential conditional powers, beyond which the trial will stop for a go or no-go
decision. This search is novel: firstly, the search is undertaken over a range of values unique
to each possible design realisation. Secondly, these values are evaluated taking into account
the possibility of early stopping. Finally, each design realisations operating characteristics are
obtained exactly.
The proposed designs are compared to existing designs in a real data example. They are also
compared under three scenarios, both with respect to four single optimality criteria and using a
loss function.
The proposed designs are superior in almost all cases. Optimising for the expected sample
size under either the null or alternative hypothesis, the saving compared to the popular Simon’s
design ranges from 22% to 55%.
Keywords: exact distribution, Simon’s design, oncology, interim analysis, curtailment
1. Introduction
Most novel treatments are found to be inefficacious, which makes the average development
cost associated with each successful treatment extremely high (Wong et al., 2019). Further, trials
themselves are expensive to run (Martin et al., 2017), and the nature of evaluating treatment
response in oncology trials means that results are not immediately available, meaning that the
trials can take time to run. This makes novel designs that can improve clinical research extremely
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valuable. Phase II clinical trials for cancer treatments often have a binary outcome, based on
change in tumour size as measured by the RECIST scale (Therasse et al., 2000), and in phase II,
these trials often contain a single arm.
Simon’s design is the most frequently used phase II design among UK clinical trials units, and
alongside single-stage trials, accounts for most phase II oncology trial designs across the world
(Jaki, 2013; Ivanova et al., 2016). In this design, an interim analysis takes place once a specified
number of results are available. At this point, the trial stops for a no-go decision if the number
of (positive) responses is not greater than some specified value, otherwise the trial continues,
recruiting the remaining patients and continuing until results are available for all patients. The
possibility of stopping for futility at this interim point before the end of the trial has the effect of
reducing the expected sample size compared to a single-stage design (Simon, 1989).
Many extensions to Simon’s design have been proposed with the aim of decreasing expected
sample size: for example, allowing stopping for a go decision at the interim analysis if the
number of responses is greater than some specified value (Shuster, 2002). Another extension
allows stopping for either go or no-go decisions as soon as the final trial decision is certain,
known as non-stochastic curtailment (NSC) (Chi and Chen, 2008). The final extension we note
is to allow stopping for either a go or no-go decision as soon as either decision becomes highly
likely, known as stochastic curtailment (SC). This approach has been described by Jennison and
Turnbull (2000) and applied to phase II clinical trials by Kunz and Kieser (2012) and Ayanlowo
and Redden (2007).
We generalise the third of these extensions, presenting two designs that reduce the expected
sample size: firstly, we propose a two-stage design that allows SC after each participants’ results,
for either a go or no-go decision.
Secondly, we propose a single-stage design that again allows SC after each participants’
results for a go or no-go decision. The methodology behind these designs, and the approaches
used to compare them to existing designs, are summarised below.
Stochastic curtailment in this paper is based on conditional power, though other approaches
exist, for example, the predictive power approach and the the parameter-free approach (Jennison
and Turnbull, 2000). The conditional power (CP) is the probability of rejecting the null hypoth-
esis, conditional on the number of participants and responses so far, and assuming an efficacious
treatment. In our proposed designs, the trial will end as soon as the CP crosses some specified
upper or lower threshold. We present equations for calculating conditional power that are accu-
rate for both stochastic and non-stochastic curtailment. Further, designs are found by searching
over a range of thresholds for CP specific to each possible trial, a novel approach. Designs have
previously been proposed that employ stochastic curtailment using a uniform sequence of con-
ditional power thresholds, and that allow stochastic curtailment for a no-go decision only (Kunz
and Kieser, 2012; Ayanlowo and Redden, 2007). We use a real data example to compare the
operating characteristics of our proposed design types to these.
The operating characteristics of curtailed designs can be estimated using simulation. How-
ever, we obtain the exact distribution for each trial’s outcomes, and so each trial’s operating
characteristics can be found without simulation error. Further, rather than find the optimal non-
curtailed design and apply stochastic curtailment to it, as in the paper of Kunz and Kieser (2012),
we take curtailment into account when searching for the optimal realisation of a design. This
means a wider range of possible designs can be examined.
Designs can be compared using a number of different optimality criteria, including the ex-
pected sample size under the null (H0-optimal) or alternative (H1-optimal) hypotheses, and the
expected sample size among the designs with the lowest maximum sample size under the null
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(H0-minimax) or alternative (H1-minimax) hypotheses. A design must also be feasible, that is, it
satisfies some chosen type I error and power. A design that is optimal under a single optimality
criterion is known as an optimal design. The best design often differs depending on the criterion
used.
In the setting of multiple optimality criteria, Jung et al. (2004) found optimal designs by cre-
ating a loss function that was a weighted combination of maximum sample size and expected
sample size under H0. Jung et al. describe a design as admissible if it has the smallest expected
loss of all possible designs, for a given weighting. Mander et al. (2012) extend this by incor-
porating expected sample size under H1 into the loss function, and by visually examining the
admissible designs in a grid covering a range of possible weights. This results in a set of admis-
sible designs, one for each combination of weights. We use this approach to compare the admis-
sible designs of each design type for a range of weights, using three sets of design parameters
(α, β, p0, p1), termed scenarios. We then determine the admissible design for each combination
of weights in each scenario. For a given combination of weights, we term the admissible design
with the smallest expected loss across all tested designs the “omni-admissible” design. We show
that the omni-admissible design for almost all possible combinations of weights belongs to a
proposed design, rather than an existing design.
Trials that employ early stopping are known to have bias in the naı¨ve estimate of the response
rate (Whitehead, 1986). As such, this may be a source of concern for investigators with a strong
interest in point estimation. However, there are a range of estimators available that take this
bias into account for two-stage designs, and we therefore provide details of how various point
estimation procedures can be extended for use with curtailed designs, and examine the resulting
point estimates in terms of bias and root mean squared error (Porcher and Desseaux, 2012).
The remainder of the paper is as follows: in the Methods section, we describe: our new de-
signs and how they differ to currently-used designs; equations for calculating CP taking stochas-
tic curtailment into account; the rationale for searching over a non-uniform sequence of CP
thresholds; how to obtain the exact distribution of trial outcomes for a design; the loss function
and some details regarding how the admissible designs are found. In the Results section, we
present one real data example and three scenarios, comparing the proposed designs to existing
designs for the stated optimality criteria. Generalising the optimality criteria to the loss function,
we also compare designs across a grid of possible combinations of weights, and produce plots
showing the best design for each combination of weights. The effect of reducing monitoring fre-
quency is examined. For one scenario, we present plots showing the admissible designs for each
design. We present plots of bias and root mean squared error in the estimates of the response
rate, for a number of estimators. In the Discussion section, we summarise the results and make
recommendations for investigators. The supplementary material contains more detail regarding
the number of CP values there are in a trial; more detail regarding the search for admissible de-
signs; plots showing expected loss and admissible designs for each design and scenario and more
detail regarding the point estimators used.
2. Methods
For a trial of the considered type, the treatment is assumed to have a true response rate p. Let
p0 be the greatest response rate that is clinically uninteresting, and p1 be the smallest response
rate that is big enough to warrant further study. We test the null hypothesis H0 : p = p0 against
the alternative hypothesis H1 : p , p0. The trial is powered under p = p1.
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2.1. Designs
For single-arm trials with a binary outcome, the most simple trial design is a single-stage trial,
which is comprised of N patients and is deemed a success if the number of responses S N exceeds
some pre-specified threshold r. Simon’s design includes an interim analysis after n1 patients, at
which point the trial proceeds to the end only if the number of responses S n1 is greater than some
r1, otherwise it stops for a no-go decision (Simon, 1989). Shuster (2002) proposed an extension
to Simon’s design, where the trial may stop for a go decision after n1 patients if the number of
responses S n1 exceeds some threshold e1. We will refer to this design as “Simon with go”. For
all designs, we use the notation (Sm,m) to denote the point in a trial where Sm responses have
been observed after m participants.
For both single-stage designs and Simon’s design, it is likely that the final go or no-go de-
cision is known before the termination of the trial: If, after m patients, Sm > r, then the trial
will be declared successful regardless of the data from the remaining patients; conversely, if
m− Sm > N − r − 1, then the trial will be declared a failure, again regardless of the data from the
remaining patients. Chi and Chen (2008) (CC) proposed NSC: this design can be understood as
Simon’s design with stopping allowed as soon as the final decision is known with certainty, for
either a go or no-go decision. We will refer to this as the “NSC design”.
Ayanlowo and Redden (2007) (AR) and Kunz and Kieser (2012) (KK) proposed trials em-
ploying SC for a no-go decision only, i.e., stopping a trial when failure is likely but not yet certain.
A range of approaches are available for SC (Jennison and Turnbull, 2000), and AR and KK use
the conditional power approach: if the probability of rejecting H0, assuming p = p1 and condi-
tional on the current number of patients and responses, is below a specified threshold, θF , the trial
is ended for a no-go decision. AR proposed stopping only in the second stage, while KK pro-
posed allowing stopping after each observation. AR examined two thresholds, θF ∈ {0.05, 0.10},
while KK examined the uniform sequence of thresholds θF ∈ {0, 0.01, . . . , 1}.
We propose two designs, where SC is permitted after each observation and where the trial
may stop not only for a no-go decision if CP < θF , but also for a go decision if CP > θE , for
some specified threshold θE . Boundaries for both θE and θF may be set, for example setting
min(θE) = 1 to allow SC for a no-go decision only. We have not employed such boundaries, only
noting that they can readily be incorporated, as our goal is to find the optimal design realisation
regardless of θE and θF values. However, boundaries may be desired, for example, for statistical
reasons, or to reduce computation time. In the supplementary material, we propose and justify
using the boundary θF < p1, and use of this boundary reduces computation time without affecting
the results. The first design we propose is an extension of Simon’s design and the NSC design:
it can be understood as an NSC design that allows stopping if either a go or no-go decision
becomes likely. This will be referred to as the “SC design”. The second design we propose
can be understood as a single-stage design that allows stopping if either a go or no-go decision
becomes likely. This will be referred to as the “m-stage design”.
The differences between the above designs are shown in Figure 1. Here, all possible points,
and whether they are terminal points, i.e., points that will cause the trial to end if reached, are
shown for the following designs: Single-stage, Simon’s design, Simon with go, NSC design, SC
design and m-stage design. This figure shows how these designs are related. It also shows in
a practical sense how the incorporation of stochastic and non-stochastic curtailment improves
expected sample size by decreasing the number of points that are possible to reach.
An objection to curtailment for a go decision is that one may wish to obtain more data if a
treatment appears promising. However, the current abundance of possible treatments to be tested
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among relatively few participants make this argument less compelling than in the past. There
may be some objections to stochastic curtailment in particular, as it allows for the termination of
a trial at a point where, under another design, the final decision is not yet certain. The primary
rebuttal to this is to make clear that the designs being proposed retain the desired type I error and
power rates; nothing is lost by employing stochastic curtailment. A more practical argument is
to note that the incorporation of stochastic curtailment into Simon’s design is no different to the
incorporation of the early stopping of Simon’s design into a single-stage design: In the Results
section, we use the example of a trial by Sharma et al. (2012), who used an optimal Simon design
of r1 = 4, n1 = 19, r = 15,N = 54. Consider a single-stage trial with the same sample size and
final stopping boundary, r = 15,N = 54. At the points in the trial where Simon’s design would
specify early stopping, Sm = 0, 1, 2, 3, 4 and m = 19, the conditional power of the single-stage
trial is 0.30, 0.43, 0.56, 0.69 and 0.80 respectively. That is to say, if the trial reached the point
(Sm = 4,m = 19), the probability of a go decision would be 0.80 conditional on p = p1 in a
single-stage trial, but would require stopping for a no-go decision under Simon’s design. Thus
any acceptance of Simon’s design is a tacit acceptance of ending a trial where, if a simpler design
was employed, the final decision would not yet be certain.
Simon SimonGO KK AR NSC SC m-stage
Allows stopping for go N Y N N Y Y Y
Exact results (i.e., no simulation) Y Y N N Y Y Y
Allows stopping after each observation N N Y N Y Y Y
Allows NSC N N Y Y Y Y Y
Allows SC N N Y Y N Y Y
Allows SC for go N N N N N Y Y
Trial-specific possible θ’s investigated — — N N — Y Y
Table 1: Comparison of methods. KK=Kunz and Kieser; AR=Ayanlowo and Redden.
The differences between various existing designs and our proposed designs are also shown
in Table 1, and in a taxonomy of possible two-stage designs in Table 2. The SC design (and
the m-stage design) allow stopping at any point in the trial, stopping when the final go or no-go
decision is certain (or likely), and exact distributions are used to obtain operating characteristics
that are free from simulation error. In addition, the proposed designs allow SC for a go decision,
and take curtailment into account while searching for possible designs.
2.2. Obtaining exact distributions
There are a number of possible sequences of participant results that lead to a point (Sm,m);
consider each possible realisation of a trial as the “path” of a trial. As an example, see Figure 2:
This example shows a possible path of a single-stage trial with no early stopping. This path may
be described as Sm = 0, 1, 1, 1, 2, 2, 3, 3,m = 1, . . . ,N. A path may end at some point m < N if
early stopping is permitted. The set PSm,m is the set of paths that have the terminal point (Sm,m).
The trials we describe progress theoretically, and often practically, one participant result at a
time, where each result is response or no response. For a single-stage trial where no early stop-
ping is allowed, the number of possible paths is 2N . Recording the probabilities of all possible
paths would allow the exact distribution of the trial outcomes to be known. Even for a trial of
moderate size, say N = 30, the number of paths (230 > 109) would make this computationally
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Two-stage design
N N N N Simon
N N N Y NA
N N Y N —
N N Y Y Simon + AR*†
N Y N N NA
N Y N Y NA
N Y Y N —
N Y Y Y Simon + KK**†
Y N N N Simon with go
Y N N Y NA
Y N Y N —
Y N Y Y NSC+AR*†
Y Y N N NA
Y Y N Y NA
Y Y Y N NSC
Y Y Y Y SC, NSC+KK**†
Table 2: Taxonomy of two-stage methods. KK=Kunz and Kieser; AR=Ayanlowo and Redden. *Stochastic curtailment
uses θF ∈ {0.05, 0.10}. **Stochastic curtailment uses θF ∈ {0, 0.01, . . . , 1}. † Stochastic curtailment for futility only. NA:
Design not possible. Dash: Design possible.
intensive. However, to obtain the exact distribution of a trial, the probability of each path is not
necessary; for any type of design, all that is required is the probability of reaching each point
(Sm,m) in the trial that results in a decision to stop, i.e., each terminal point. With these proba-
bilities known, the probabilities of reaching the terminal points that result in a go decision can be
summed under the assumptions p = p0 and p = p1 to obtain type I error and power, respectively.
Moreover, it is possible to obtain the CP of a trial at any point (Sm,m), as detailed below. The ex-
pected sample size can be obtained by multiplying the number of participants m at each terminal
point by the probability of its occurrence. Using the exact distribution means that the operating
characteristics of the trial outcomes — for example, overall type I error, power, expected sample
size and so on — are known without recourse to simulation. This is essential when searching for
the true optimal design, as simulation error could result in a design with a non-optimal expected
sample size being chosen.
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2.3. Conditional Power
The conditional probability at point (Sm,m) is the probability of rejecting H0 conditional on
being at point (Sm,m) and assuming a true response rate p. Setting p = p1 gives the conditional
power CP(p1)Sm,m. However, from here we refer only to conditional power rather than condi-
tional probability. Kunz and Kieser (2012) previously provided an equation for calculating CP,
but this equation did not account for early stopping. For the NSC design, we have derived the
following equation for calculating CP(p1)Sm,m:
CP(p1)Sm,m =

0, if m − Sm > N − r − 1
or (m − Sm > n1 − r1 − 1 and m ≤ n1)
n1−m−1∑
j=r−Sm
A( j, r1) N−( j+m+1)−1∑
i=r−Sm
A(i, r)
 , if m − Sm ≤ n1 − r1 − 1 and m ≤ n1
N−m−1∑
i=r−Sm
A(i, r) if m − Sm ≤ N − r − 1 and m > n1
1, if Sm > r

(1)
where
A(x, y) =
(
x
y − Sm
)
py−Sm+11 (1 − p1)x−(y−Sm).
The CP for the NSC design can also be written recursively as
CP(p1)Sm,m =

0, if m − Sm > N − r − 1 or (m − Sm > n1 − r1 − 1 and m ≤ n1)
D, if m − Sm ≤ N − r − 1 or (m − Sm ≤ n1 − r1 − 1 and m ≤ n1)
1, if Sm > r
 , (2)
where D = p1CP(p1)Sm+1,m+1 + (1 − p1)CP(p1)Sm,m+1. For a single-stage trial incorporating
NSC, the CP can be obtained using these equations by omitting the conditions relating to r1 and
n1. In its recursive form, it can be seen that the CP at any point in a trial is a function of the CP at
points with more responses and more participants, if such points exist. Consider a matrix of CP
values for an NSC design based on number of responses Sm as rows and number of participants
m as columns. As an example, let the maximum sample size be N = 8 and the stopping boundary
be r = 4, as in Figure 1 (d). The CP at the point (Sm = 3,m = 4), CP(p1)3,4, is a function of
CP(p1)3,5 and CP(p1)4,5, which in turn are a function of CP(p1)3,6 and CP(p1)4,6, and CP(p1)4,6
and CP(p1)5,6 respectively.
For designs that incorporate NSC, the trial stops and a no-go decision is taken if CP = 0.
The trial stops and a go decision is taken if CP = 1. The CP at any point can be obtained using
Equation (1) directly. For designs that incorporate SC, the trial will additionally end at any point
where 0 < CP < θF or θE < CP < 1. As the CP is a function of later points in the trial, the
predetermined decision to end a trial at any point where 0 < CP < θF effectively causes the CP
of such points to be rounded to zero. Conversely, points where θE < CP < 1 are rounded to one.
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This in turn affects the CP of earlier points in trial. As such, when incorporating SC, it is logical
to calculate CP at each point using a recursive equation, one value at a time, starting at the point
(Sm = r,m = N − 1), where CP(p1)r,N−1 = p1. All “earlier” points, in the trial, i.e., points such
that m < N − 1, are either a function of CP(p1)r,N−1 or are stopping boundaries. For points with
more responses or more participants, CP(p1)a,N = 0 if a ≤ r, and CP(p1)a,b = 1 for any a > r
and any b. Thus for the SC design, the CP at each point can be obtained using the following
equation:
CP(p1)Sm,m =

0, if D < θF or m − Sm > N − r − 1 or (m − Sm > n1 − r1 − 1 and m ≤ n1)
D, if θF ≤ D ≤ θE and {m − Sm > N − r − 1 or (m − Sm > n1 − r1 − 1 and m ≤ n1)}
1, if D > θE or Sm > r
 .
(3)
As an analogue to the equations for NSC designs, Equation (3) can also be used to obtain
the CP for the m-stage design, which is essentially a single-stage design that incorporates SC, by
omitting the conditions relating to r1 and n1.
2.4. Choosing thresholds θF and θE
Define θ as the set of values from which ordered pairs of θF and θE (such that θF < θE) will be
created and searched over to find admissible designs. One could use a uniformly distributed set
of possible thresholds to some specified degree of coarseness. However, by choosing a uniform,
coarse set of values of θ to search over, some designs with good operating characteristics may
be missed. Conversely, undertaking a fine search would be computationally intensive — for
example, the sequence {0, 0.001, . . . , 1} produces 500,500 ordered pairs (θF , θE). Aside from the
computational intensity required, undertaking a search over a fine uniform grid may still result in
missing potential designs. This is because the effect of a chosen threshold θF or θE depends on
the conditional power at each possible point in the trial. Consider for example, the NSC design
shown in Figure 1 (d): for each possible combination of participants so far, m, and number of
responses, Sm, there exists some conditional power, CP(p1)Sm,m. At the points where the trial
stops for a go or no-go decision, the CP is equal to one or zero respectively, and is strictly between
these values at all other points. Further, in trials of this type, the CP values are not uniformly
distributed; instead, most of the mass is close to zero or one. This is shown for three example
trials in Figure 3. To account for the lack of a uniform distribution, we propose searching over
a set of thresholds chosen based on the conditional power at each point in each possible trial.
We note every possible value of CP(p1)Sm,m, including zero and one, for a given combination of
{r,N} or {r1, n1, r,N}, and use this as the trial-specific set θ. We search over ordered pairs (θF , θE)
from elements of this set such that θF < θE . For an NSC design with typical design parameters
(r1 = 5, n1 = 20, r = 10, n = 40, p0 = 0.1, p1 = 0.3), there are 239 possible CP values, from
which 28,441 possible ordered pairs can be created. Placing sensible constraints on the ordered
pairs, such as θF < p1, θE ≥ 0.95, reduces the number of possible ordered pairs to 7,809, with
such constraints justified in the supplementary material.
2.5. Admissible design search
For the proposed designs, possible design realisations are found by first setting the desired
type I error and power, p0 and p1, and a range for N. For each N, a sensible range for r is
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chosen based on bounds suggested by either Ahern (2001) or Wald (1947); see the supplementary
material for details. The combinations of {r,N} are stored, as are possible combinations of r1 and
n1 in the case of two-stage designs. Let R be the set of all possible combinations of {r,N} or
{r1, n1, r,N}. For eachR, the CP of each point in that trial is obtained. These CPs form the trial-
specific set θ. Within each R, type I error, power, expected sample size under p = p0(E(N |p =
p0)) and p = p1(E(N |p = p1)) are found for ordered pairs (θF , θE) ∈ θ : θF < θE . The dominated
designs — designs that are not superior to at least one other design in terms of E(N |p0), E(N |p1)
or N — are discarded. What remains is a collection of admissible designs. The expected sample
sizes of the H0- and H1-optimal and H0- and H1-minimax admissible designs of the proposed
designs will be compared to those of Simon’s design, Simon with go and the NSC design, and
additionally to those of the designs found using the sequential probability ratio test of Wald
(1947) in the case of the H0- and H1-optimal criteria. Wald’s sequential probability ratio test is a
design that produces trials that are feasible and have low E(N |p0) and E(N |p1), but no maximum
sample size. More details of this design are provided in the supplementary material.
Note that type I error and power are not calculated prior to adding curtailment, as a design
that is feasible under SC may not be feasible before the incorporation of SC, and so if such
designs were discarded in advance, they would be missed. An example of such an instance is
provided in the supplementary material.
2.6. The loss function
Jung et al. (2004) introduced the concept of choosing a design based not on a single optimality
criterion, but instead on a combination of two optimality criteria, weighted in importance by
an investigator. This was extended by Mander et al. (2012) to an expected loss function with
weights on three optimality criteria: Expected sample size under the null hypothesis E(N |p0),
the expected sample size under the alternative hypothesis E(N |p1) and maximum sample size N.
The expected loss function is
L = q0E(N |p0) + q1E(N |p1) + (1 − q0 − q1)N,
where q0, q1 ∈ [0, 1] and q0 + q1 ≤ 1. In Mander et al., the admissible designs — defined
as the design realisations with the smallest expected loss for a given set of weights — were
plotted for a grid of all possible combinations of weights. We extend this concept to allow the
comparison of design realisations across differing designs: for each combination of weights,
the realisation with the lowest loss, L, across all designs is found, and the design to which it
belongs is termed the “omni-admissible” design for that combination of weights. Across a grid
of possible combinations of weights, the design to which each omni-admissible design belongs
is plotted. In addition, the difference between the expected loss of two designs at each set of
weights is quantified, for certain pairs of designs. The values have no intrinsic meaning; their
only purpose is to facilitate the comparison of designs. For brevity, the set of admissible designs
for each design is plotted for the first scenario only, with the remainder in the supplementary
material. From these plots, the number of admissible designs, and the range of weights for
which each admissible design has the lowest loss, can be seen.
2.7. Inference: Estimation of response rate
Though not the main aim of phase II trials, it is of importance to undertake inference using
the final trial data in order to help make decisions about possible future trials. In particular,
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one may estimate the response rate of a treatment. The MLE of the response rate is the ob-
served response rate pˆ = Sm/m, where m represents the number of participants after which the
trial stopped. However, this estimator is biased in trials that allow stopping at an interim anal-
ysis, and as such there are a number of estimators available with the aim of reducing this bias
(Porcher and Desseaux, 2012). However, such estimators have only been previously presented
for two-stage designs. To address possible concerns regarding point estimation in curtailed de-
signs, we examine estimates of the response rate across existing and novel designs, from five
estimators, extended to the multi-stage case: the naı¨ve estimator, that is, the MLE above; the
bias-adjusted estimator (Chang et al., 1989); the simplified bias subtraction estimator (Guo and
Liu, 2005); the median unbiased estimator (MUE) (Koyama and Chen, 2008) and the uniformly
minimum-variance unbiased estimator (UMVUE) (Jung and Kim, 2004). A range of estimators
are used as there is no single estimator that performs best in all situations. We report the bias,
Bias( pˆ|p) = E(pˆ|p) − p, and the RMSE. The RMSE, RMSE( pˆ|p) = √(Bias( pˆ|p))2 + Var( pˆ|p),
where Var( pˆ|p) = E( pˆ2|p) − E(pˆ|p)2, is equivalent to taking the square root of the weighted
average of the squared distances between each possible point estimate and the true value. For
brevity, more details regarding each estimator is provided in the supplementary material. The
results are shown for the H0-optimal admissible designs of each design.
3. Results
3.1. Real data example
Kunz and Kieser (2012) present a real data example from Sharma et al. (2012). In this trial,
the following design parameters were chosen: α = 0.05, β = 0.1, p0 = 0.2, p1 = 0.4. Kunz
and Kieser compare the following combinations of designs to the optimal Simon design: optimal
Simon design with NSC for no-go only, SC for no-go only, and early stopping in stage 2 only
(“Simon + AR”); optimal Simon design with NSC for no-go only, SC for no-go only, and early
stopping in both stages (“Simon + KK”); optimal Simon design with NSC for go and no-go,
SC for no-go only, and early stopping in stage 2 only (“CC + AR”); optimal Simon design with
NSC for go and no-go, SC for no-go only, and early stopping in both stages (“CC + KK”). The
threshold θF = 0.4 is used, as Kunz and Kieser directly report the results for only θF = 0.4 and
θF = 0.6, stating that trials using θF = 0.6 do not achieve requisite power. Table 3 contains
the operating characteristics for these designs to as great an extent as possible, in addition to
those from: Simon’s design; the NSC design (“CC”); two SC designs, the former chosen for its
resemblance to the other compared trials in terms of maximum sample size N, the latter chosen
as it is the H0-optimal design; two m-stage designs, chosen in the same manner as the SC designs,
and finally Wald’s sequential probability ratio test (Wald, 1947). The operating characteristics
of Simon+AR, Simon+KK, CC+AR and CC+KK were obtained from the results of Kunz and
Kieser (2012) and from Stata using the simontwostage package (Kunz and Kieser, 2011). The
maximum N searched over for the SC and m-stage designs respectively is N = 58 and N = 94,
due to computational intensity, with the range of r chosen based on the boundaries of Wald
(1947) (see supplementary material).
It can be seen from Table 3 that with the exception of Wald, the designs with the lowest
E(N |p0) are Simon+KK and CC+KK, which use a threshold of θF = 0.4 and allow stopping
at any point. However, these designs did not obtain the requisite type I error of 0.05 in the
simulation undertaken. The four trials from the two proposed designs achieve a lower E(N |p0)
than all feasible designs, with the exception of Wald, while maintaining the necessary type I and
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type II errors. They also have lower thresholds for stopping for a no-go decision compared to
other designs that use SC, with a maximum of θF = 0.228 compared to θF = 0.4. Further, the
first m-stage design has a lower maximum sample size than all other designs.
The study ended at the first stage, with 1 response out of 19 participants. Using NSC only, the
study would have ended after 16 participants. However, using the m-stage design optimised for
E(N |p0), the study would have ended after 8 to 11 participants, the final stopping point dependent
on when the single response occurred.
Design r1 n1 r n2 N α Power E(N|p0) E(N |p1) θF θE
Simon 4 19 15 35 54 0.048 0.904 30.4 51.6 – –
CC 4 19 15 35 54 0.048 0.904 28.2 37.6 0.000 1.000
Simon + AR 4 19 15 35 54 – 0.90 26.6 – 0.400 1.000
Simon + KK 4 19 15 35 54 0.054 0.904 21.3 – 0.400 1.000
CC + AR 4 19 15 35 54 – 0.90 25.4 – 0.400 1.000
CC + KK 4 19 15 35 54 0.054 0.904 21.0 – 0.400 1.000
SC1 2 14 15 40 54 0.050 0.901 23.0 26.6 0.164 0.998
SC2 4 21 17 37 58 0.050 0.900 22.6 25.5 0.199 0.998
m-stage1 – – 15 – 52 0.049 0.909 25.3 25.8 0.135 0.996
m-stage2 – – 26 – 94 0.049 0.902 22.1 23.3 0.228 0.998
Wald – – – – – 0.050 0.900 21.8 22.7 – –
Table 3: Comparison of designs, with design parameters (α, β, p0, p1) = (0.05, 0.10, 0.20, 0.40). CC identical to NSC
design. Blanks in α and E(N|p1) due to data not being included in Kunz and Kieser and not being reproducible.
3.2. Example trials
Three sets of design parameters, or scenarios, were used to compare five designs: Simon’s
design; Simon with go; the NSC design; the SC design and the m-stage design. For each scenario
and design, a set of admissible designs was obtained as described above. For Simon and Simon
with go, the maximum sample size searched over was 20% greater than the maximum sample
size of the H0-optimal design, as in Mander et al. (2012). For NSC and m-stage, the maximum
sample size searched over was set to 80, approximately 2-3 times greater than the maximum
sample size for the admissible Simon’s designs under H0-optimal and H0-minimax. For SC,
maximum sample size was 43 to 47, due to computational intensity. For the proposed designs,
the range of r was chosen based on the bounds of Ahern (2001) {bNp0c , dNp1e}, though the final
set of admissible designs all contained values of r that were also within the (stricter) bounds of
Wald (1947). Also reported is E(N|p0) and E(N|p1) from Wald’s sequential probability ratio test.
As Wald’s probability ratio test seeks to minimise expected sample size and has no maximum
sample size, the expected sample sizes from this test will be compared to those obtained under
the H0- and H1-optimal criteria.
3.3. Scenario 1: Design parameters (α, β, p0, p1) = (0.05, 0.15, 0.1, 0.3)
Table 4 shows the optimal design for each compared design, for four optimality criteria:
H0-optimal, H1-optimal, H0-minimax and H1-minimax. For all four optimality criteria, the
optimal designs of the proposed designs outperform those of the existing two-stage designs,
and employ thresholds of θF < 0.23 and θE > 0.98 in each case. With the exception of
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the SC design under H1-optimal, the proposed designs have lower expected sample sizes un-
der both the null and alternative hypotheses. The expected sample sizes from Wald’s test are
E(N |p0) = 13.9, E(N |p1) = 13.9, comparable to those of the m-stage design. Note that under
the minimax criteria, the SC design happens to be the m-stage design with the addition of one
explicit interim analysis.
The design with the lowest expected loss across all those compared, the omni-admissible
design, is shown in Figure 4 (a). Across all combinations of weights, the omni-admissible design
is either the SC design or the m-stage design. The difference in expected loss between SC and
m-stage admissible designs is shown in Figure 4 (b). It shows that while the m-stage design has
a considerably lower loss score near the triangle’s hypotenuse, that is, when there is low weight
on maximum sample size N, the SC has a similar loss score to the m-stage design otherwise,
especially as weight of N approaches the maximum. The maximum difference between a superior
SC design and inferior m-stage design is 3.0. The range of expected loss across all admissible
designs of all design types is (14.1, 79.4), with median 23.1 (IQR [19.2, 26.6]).
3.4. Admissible designs, by design type — scenario 1 only
In Figure 5, the admissible designs are shown for each combination of weights, for scenario
1. For completeness, corresponding figures are shown for scenarios 2 and 3 in the supplementary
material. The plots of admissible designs for Simon’s and Simon with go designs, Figures 5(a)
and 5(b), match those obtained by Mander et al. (2012) as do the corresponding plots in the
supplementary material. The overall results are similar across all three scenarios: the proposed
designs generally contain a greater number of admissible designs across the combinations of
weights examined than existing designs. For the proposed designs, the admissible design regions
often contain slopes parallel to the hypotenuse, suggesting that the admissible design may be
more dependent on the weight of N than E(N |p0) or E(N |p1). In some cases, this is manifested
in long, thin regions near the hypotenuse. At the hypotenuse, the admissible designs have the
greatest maximum sample size of all the possible admissible designs, with maximum sample
size decreasing as the weight of N increases (that is, towards the bottom left corner), as could be
expected. When the weight on N is not close to one, the novel designs often have a maximum
sample size similar to those that do not employ curtailment.
3.5. Scenario 2: Design parameters (α, β, p0, p1) = (0.05, 0.2, 0.1, 0.3)
Scenario 2 decreases the required power by 0.05 to 0.80. Table 5 shows the optimal designs
for each design across the four specified criteria. The two proposed designs outperform the
existing designs under H0- and H1-optimal. Under H0- and H1-minimax, Simon with go has a
lower maximum sample size (n = 24 vs n = 25 for all others), though E(N |p0) and E(N|p1) for
the proposed designs are considerably lower. Under all four criteria, the expected sample sizes
of the proposed designs under both the null and alternative hypotheses are lower than those of
the existing designs, and the thresholds satisfy θF < 0.22 and θE > 0.97. Again, the expected
sample sizes of Wald are comparable to those of the m-stage design, and again the SC design
happens to be the m-stage design with the addition of one explicit interim analysis.
Figure 6(a) shows that the omni-admissible design is SC for most sets of weights, with ex-
ceptions where the weight of N is either close to one (as Simon with go has the lowest N of any
design) or close to zero, where m-stage is superior. Figures 6(b) and 6(c) show that even in the
region where the Simon with go design is superior, the loss scores of the SC and m-stage admis-
sible designs are similar and as such, should be considered comparable in terms of optimality.
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The maximum difference in loss score in favour of Simon with go compared to both the SC and
m-stage designs is 1.0. Figure 6(d) shows that the difference in expected loss between SC and
m-stage is small, less than 0.9 at all points, while the range of loss scores across all admissible
designs in this scenario (11.7, 75.4), with median 20.4 (IQR [17.3, 23.2]).
3.6. Scenario 3: Design parameters (α, β, p0, p1) = (0.05, 0.2, 0.2, 0.4)
Scenario 3 increases both p0 and p1 by 0.1, resulting in the design parameters (α, β, p0, p1) =
(0.05, 0.2, 0.2, 0.4). Table 6 shows the optimal designs for the four optimality criteria. The pro-
posed designs outperform the existing designs under all four criteria. In particular, the minimum
maximum sample sizes of the proposed designs are lower than those of the Simon and NSC
designs. The admissible m-stage designs under H0- and H1-optimal have comparable expected
sample sizes to that of Wald, under both the null and alternative hypotheses. The admissible
designs for H0- and H1-minimax are identical. The conditional power thresholds of the proposed
designs satisfy θE > 0.98 and θF < 0.23 for all designs.
Figure 7(a) shows that each omni-admissible design across the range of possible weights is
again either SC or m-stage. The difference in expected loss between these two designs is shown
in Figure 7(b). The difference is small, < 1.1 at all points, compared to the range of loss scores
across all admissible designs in this scenario (15.0, 64.5), with median 26.4 (IQR [22.7, 30.4]).
3.7. Continuous monitoring in practice and effect of reduced monitoring frequency
There may be some practical objection to the continuous monitoring required by the SC and
m-stage designs. However, trial recruitment rate is often lower than expected: in a review of 122
trials, Campbell et al. (2007) found that early participant recruitment was slower than expected
in 77 (63%) of 122 reviewed trials, and a review of 151 randomised controlled trials by Walters
et al. (2017) reported a median recruitment rate of 0.92 participants per centre per month. Further,
Campbell et al. (2007) found that only 38 (31%) of 122 trials reached their intended sample size
and 66 (54%) requested a trial extension. As such, trial recruitment rates are generally lower
than anticipated, and low enough to facilitate continuous monitoring, especially as no additional
statistical analysis is required to use stochastic curtailment; all stopping boundaries are obtained
in advance.
If trial recruitment rate is anticipated to be so great as to make continuous monitoring im-
practical, a design permitting stochastic curtailment only after every block of B participants may
be considered. Such an approach can still produce savings in expected sample size. As an
example, Table 7 shows admissible designs for blocks of size four and eight, that is, permitting
curtailment after every four or eight participants respectively, for the first scenario (α, β, p0, p1) =
(0.05, 0.15, 0.10, 0.30). These are shown alongside the admissible designs for the Simon design
and the m-stage design. The m-stage design may be considered as using blocks of size one.
Under the H0- and H1-optimal criteria, the designs permitting stochastic curtailment only after
every four or eight participants produce considerable savings in expected sample size compared
to using Simon’s design. Under the H0- and H1-minimax criteria, which are combined in the
table as the admissible designs are identical in this instance, savings in expected sample size are
again made, with the exception of E(N |p0) when using block size eight.
3.8. Estimation (scenario 1, selected)
Bias and root mean squared error (RMSE) in the response rate estimates are shown in Figure
8, with the maximum absolute bias and RMSE shown in Table 8. For brevity, the only plots
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shown are for the H0-optimal designs for scenario 1. In Simon’s and the Simon with go designs,
the estimates of bias are close to zero for all estimators (Figures 8(a), 8(c)). For designs that
employ curtailment, the bias adjusted, bias subtracted MUE and UMVUE estimators remain
close to zero, while the naı¨ve estimator gives less accurate estimates (Figures 8(e), 8(g), 8(i)).
Overall, bias and RMSE is only slightly poorer among the proposed designs than the Simon-
based designs for p < p1. For greater p, the poorer estimates among the proposed designs are a
result of the trial being curtailed with fewer patients compared to the Simon-based designs. The
maximum absolute bias is similar across designs, with the exception of somewhat greater bias
among the two SC designs under the naı¨ve estimator (Table 8).
The RMSE of the estimates gradually increase as the degree of early stopping increases,
with the increase being more pronounced at less likely response rates, though RMSE decreases
sharply to zero when the response rate is close to one. The maximum RMSE for the two SC
designs is somewhat greater than the rest (Table 8).
4. Discussion
This paper introduces two new designs for binary outcome, single-arm phase II clinical trials,
one based on Simon’s design and one based on the single-stage design. These designs propose
allowing early stopping to make a go or no-go decision before the final decision would otherwise
be certain, known as stochastic curtailment.
In addition to these proposed designs, this paper also introduces four approaches for improv-
ing a search for an optimal design: firstly, the exact distribution of the trial outcomes is obtained,
allowing the trial’s operating characteristics to be known without simulation error. Secondly, a
new approach is proposed for finding relevant stopping boundaries when using stochastic curtail-
ment, based on the conditional power at each point in each possible trial, allowing more potential
designs to be evaluated. Thirdly, the conditional power at each point in each potential design is
calculated taking the possibility of stochastic curtailment into account; it is not calculated based
on an approximation that does not account for stopping due to stochastic curtailment. Finally,
type I error and power are only calculated after taking curtailment into account; no designs are
discarded in advance for not reaching the required type I error and power in their uncurtailed
form. Between them, these four concepts serve dual purposes: to allow more potential designs
to be examined without excessive computational intensity, and to increase the accuracy of the
reported operating characteristics of such designs. This should result in investigators being able
to make a more efficient choice of design for any potential study.
The proposed designs, combined with the above approaches, were compared to a number of
existing curtailed designs. They were compared in a real data example, where they were shown
to approximately halve the trial sample size from 19 to between 8 and 11, and also across three
scenarios with regard to the following optimality criteria: H0-optimal, H1-optimal, H0-minimax
and H1-minimax. With the exception of the H0/H1-minimax criteria in one scenario, where
the proposed designs had a maximum sample size of 25 compared to 24 in an existing design,
the proposed designs were superior across all criteria and scenarios. For the proposed designs,
the expected sample size under the H0-optimal and H1-optimal criteria was comparable to those
obtained using Wald’s sequential probability ratio test, with a difference of less than a single
participant in general, in favour of Wald’s test. However, while this test may result in favourable
expected sample size, a design with no maximum sample size would be impractical for clinical
trials, where a maximum sample size is necessary due to limited resources, population size and
so on.
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The proposed designs were also compared to existing designs across a combination of mul-
tiple criteria, using a weighted loss function. Employing Mander et al’s expected loss function,
admissible designs were obtained for each design over a grid of combination of weights for the
criteria maximum sample size, expected sample size under the null hypothesis and expected
sample size under the alternative hypothesis. For each possible combination of weights, the de-
sign realisation that had the lowest expected loss across all designs was recorded, and the design
to which it belonged was recorded. This design has been termed the omni-admissible design.
Plotting the omni-admissible design for each possible combination of weights, it is shown that
the proposed designs are almost always better in terms of expected loss. While the two-stage
stochastic curtailment design can be superior to the m-stage design, the difference is generally
slight. However, we accept that increasing the maximum N searched over is likely to find de-
sign realisations with lower expected sample size, and the disparity between the SC and m-stage
searches in terms of maximum N searched over may be the reason why the omni-admissible
design is an m-stage rather than an SC design for some combinations of weights. Searching for
m-stage admissible designs is approximately two orders of magnitude faster than the SC design,
with a full search able to be conducted in under 60 minutes for N ∈ [20, 80]. For this reason,
we recommend that investigators focus on this design. The effect of reducing the frequency of
monitoring, was examined. It was shown that considerable savings in expected sample size may
still be made even when employing designs with less frequent monitoring.
There may be some apprehension regarding ending a trial before the final decision is certain
compared to a different design. However, the trials are powered taking this into account, in the
same way that Simon’s design meets the required type I error and power despite allowing the
potential for stopping before the final decision is certain compared to a single-stage trial. Indeed,
we have shown that a Simon design may end for a no-go decision even when the probability of
success for an effective treatment in a single-stage design is as much as 0.80. Further, across
all admissible designs obtained from the proposed designs, the threshold for stopping for a go
decision is close to one, θE > 0.97. Finally, if necessary, it is possible to allow the specification
of limits to the thresholds θF and θE to ranges that are acceptable to the investigator.
These design types could be generalised in a number of ways in future work. In case of
a desire to collect a certain degree of information in a trial, a trial could be specified to end
only after data is available for a minimum of n participants. Secondly, estimates of confidence
intervals and p values could be compared to those from existing design types. Finally, the effect
of multi-participant cohorts could be examined.
In summary, this paper proposes two designs for phase II, single arm, binary outcome clinical
trials, and augments them with a number of approaches for finding better designs, using exact
distributions so that the designs’ operating characteristics can be obtained without simulation
error. These designs, combined with the proposed approaches, have been shown to be superior
to existing designs, both when considering a single optimality criterion and when considering a
weighted combination of multiple criteria.
The data that support the findings of this study are available from the corresponding author
upon reasonable request.
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Figure 1: Illustrative diagrams of different trial designs, showing potential paths where the study would end, known as
terminal points. Designs: (a) Single stage design; (b) Simon’s design; (c) Simon with go; (d) NSC; (e) SC; (f) m-stage.
m: Number of participant results so far. Sm: Number of responses so far. All trials have N = 8, r = 4, with r1 = 1 in the
two-stage designs and e1 = 3 in Simon’s design with go and no-go stopping.
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Figure 2: Example of a path for a single-stage trial with N = 8.
Figure 3: Cumulative distribution function of unique conditional power values for NSC designs (format {r1/n1, r/N})
with r = Np0,N(p0 + p1)/2 and Np1 for N = 40, 60 and 80 respectively, r1 = r/2, n1 = N/2, p0 = 0.1 and p1 = 0.3.
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r1 e1 n1 r n2 n E(N |p0) %Sp0 E(N |p1) %Sp1 θF θE
H0-optimal
Simon 1 11 6 24 35 18.3 1.00 32.3 1.00
Simon go 1 4 11 6 24 35 18.2 1.00 27.2 0.84
NSC 1 13 5 15 28 17.6 0.97 18.5 0.57 0.000 1.000
SC 4 27 7 14 41 14.3 0.78 15.0 0.46 0.186 0.993
m-stage 13 80 14.1 0.77 14.4 0.45 0.226 0.997
H1-optimal
Simon 2 18 5 9 27 20.4 1.00 26.5 1.00
Simon go 0 3 13 6 17 30 25.1 1.23 20.0 0.76
NSC 1 13 5 15 28 17.6 0.87 18.5 0.70 0.000 1.000
SC 4 24 8 19 43 15.5 0.76 14.6 0.55 0.126 0.984
m-stage 12 66 14.3 0.70 14.4 0.54 0.189 0.990
Wald 13.9 0.68 13.9 0.52
H0-minimax
Simon 2 18 5 9 27 20.4 1.00 26.5 1.00
Simon go 1 4 14 5 13 27 19.3 0.95 21.0 0.79
NSC 2 18 5 9 27 19.3 0.95 18.7 0.71 0.000 1.000
SC 0 10 5 17 27 17.1 0.84 16.3 0.62 0.070 0.990
m-stage 5 27 18.7 0.92 16.6 0.63 0.084 0.990
H1-minimax
Simon 2 18 5 9 27 20.4 1.00 26.5 1.00
Simon go 1 4 15 5 12 27 20.3 0.99 20.8 0.78
NSC 2 18 5 9 27 19.3 0.95 18.7 0.71 0.000 1.000
SC 4 24 5 3 27 18.8 0.92 15.8 0.60 0.050 0.986
m-stage 5 27 18.7 0.92 16.6 0.63 0.084 0.990
Table 4: Admissible designs for each design type, Scenario 1: (α, β, p0, p1) = (0.05, 0.15, 0.10, 0.30). For all designs,
requisite type I error and power is reached. Columns %Sp0 and %Sp1 show expected sample size as a proportion of
Simon’s design under p = p0 and p = p1 respectively.
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Figure 4: The omni-admissible design and difference in loss scores between the SC and m-stage admissible designs
(positive favours m-stage), scenario 1 (α, β, p0, p1) = (0.05, 0.15, 0.10, 0.30).
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Figure 5: Admissible designs for scenario 1 (α, β, p0, p1) = (0.05, 0.15, 0.10, 0.30). Designs: (a) Simon’s design; (b)
Simon with go; (c) NSC; (d) SC; (e) m-stage.
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r1 e1 n1 r n2 n E(N |p0) %Sp0 E(N |p1) %Sp1 θF θE
H0-optimal
Simon 1 10 5 19 29 15.0 1.00 26.2 1.00
Simon go 1 4 10 5 19 29 15.0 1.00 23.3 0.89
NSC 1 10 5 19 29 14.1 0.94 17.1 0.66 0.000 1.000
SC 5 33 7 10 43 11.7 0.78 13.3 0.51 0.216 0.994
m-stage 9 53 11.7 0.78 12.9 0.49 0.216 0.991
H1-optimal
Simon 2 18 5 7 25 19.9 1.00 24.6 1.00
Simon go 0 3 13 5 11 24 20.8 1.05 17.5 0.71
NSC 1 10 5 19 29 14.1 0.71 17.1 0.70 0.000 1.000
SC 3 19 8 24 43 12.5 0.63 13.0 0.53 0.163 0.980
m-stage 13 76 11.7 0.59 12.8 0.52 0.219 0.992
Wald 11.5 0.58 12.4 0.50
H0-minimax
Simon 1 15 5 10 25 19.5 1.00 24.6 1.00
Simon go 2 4 19 5 5 24 20.3 1.04 20.2 0.82
NSC 1 15 5 10 25 18.4 0.94 18.4 0.75 0.000 1.000
SC 0 9 5 16 25 15.3 0.79 14.6 0.59 0.058 0.973
m-stage 5 25 15.5 0.79 14.6 0.59 0.090 0.972
H1-minimax
Simon 2 18 5 7 25 19.9 1.00 24.6 1.00
Simon go 0 3 13 5 11 24 20.8 1.05 17.5 0.71
NSC 2 18 5 7 25 18.8 0.95 18.4 0.75 0.000 1.000
SC 0 9 5 16 25 15.3 0.77 14.6 0.59 0.058 0.973
m-stage 5 25 15.5 0.78 14.6 0.60 0.090 0.972
Table 5: Admissible designs for each design type, Scenario 2: (α, β, p0, p1) = (0.05, 0.20, 0.10, 0.30). For all designs,
requisite type I error and power is reached. Columns %Sp0 and %Sp1 show expected sample size as a proportion of
Simon’s design under p = p0 and p = p1 respectively.
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Figure 6: Omni-admissible design and difference in loss scores between the following pairs of admissible designs: Simon
with go and SC (positive favours SC), Simon with go and m-stage (positive favours m-stage) and SC and m-stage (positive
favours m-stage). Scenario 2 (α, β, p0, p1) = (0.05, 0.20, 0.10, 0.30).
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r1 e1 n1 r n2 n E(N |p0) %Sp0 E(N |p1) %Sp1 θF θE
H0-optimal
Simon 3 13 12 30 43 20.6 1.00 37.9 1.00
Simon go 3 7 13 12 30 43 20.5 1.00 35.0 0.92
NSC 3 13 12 30 43 18.8 0.91 27.8 0.73 0.000 1.000
SC 9 35 13 12 47 15.1 0.73 20.5 0.54 0.222 0.996
m-stage 17 60 15.0 0.73 18.9 0.50 0.219 0.993
H1-optimal
Simon 4 18 10 15 33 22.3 1.00 31.6 1.00
Simon go 3 6 16 11 19 35 23.1 1.04 24.8 0.78
NSC 4 18 10 15 33 20.4 0.92 25.1 0.80 0.000 1.000
SC 13 44 14 3 47 15.8 0.71 19.1 0.60 0.146 0.986
m-stage 19 65 15.1 0.68 18.7 0.59 0.209 0.990
Wald 14.7 0.66 18.2 0.58
H0-minimax
Simon 4 18 10 15 33 22.3 1.00 31.6 1.00
Simon go 2 6 15 10 17 32 24.9 1.12 24.9 0.79
NSC 4 18 10 15 33 20.4 0.92 25.1 0.80 0.000 1.000
SC 0 11 10 21 32 21.3 0.96 20.9 0.66 0.050 0.985
m-stage 10 32 21.5 0.96 20.9 0.66 0.050 0.985
H1-minimax
Simon 4 18 10 15 33 22.3 1.00 31.6 1.00
Simon go 2 6 15 10 17 32 24.9 1.12 24.9 0.79
NSC 4 18 10 15 33 20.4 0.92 25.1 0.80 0.000 1.000
SC 0 11 10 21 32 21.3 0.96 20.9 0.66 0.050 0.985
m-stage 10 32 21.5 0.96 20.9 0.66 0.050 0.985
Table 6: Admissible designs for each design type, Scenario 3: (α, β, p0, p1) = (0.05, 0.20, 0.20, 0.40). For all designs,
requisite type I error and power is reached. Columns %Sp0 and %Sp1 show expected sample size as a proportion of
Simon’s design under p = p0 and p = p1 respectively.
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Figure 7: Omni-admissible design, and difference in loss scores between SC and m-stage designs (positive favours m-
stage), scenario 3 (α, β, p0, p1) = (0.05, 0.20, 0.20, 0.40).
r1 n1 r n2 n E(N |p0) %Sp0 E(N|p1) %Sp1 θF θE
H0-optimal
Simon 1 11 6 24 35 18.3 1.00 32.3 1.00
m-stage 13 80 14.1 0.77 14.4 0.45 0.226 0.997
Block size 4 10 56 14.5 0.79 16.3 0.50 0.534 0.988
Block size 8 12 72 16.1 0.88 19.4 0.60 0.691 0.991
H1-optimal
Simon 2 18 5 9 27 20.4 1.00 26.5 1.00
m-stage 12 66 14.3 0.70 14.4 0.54 0.189 0.990
Block size 4 11 64 14.7 0.72 16.1 0.61 0.550 0.991
Block size 8 16 80 16.8 0.82 18.2 0.69 0.559 0.974
H0/1-minimax
Simon 2 18 5 9 27 20.4 1.00 26.5 1.00
m-stage 5 27 18.7 0.92 16.6 0.63 0.084 0.990
Block size 4 6 32 18.8 0.92 18.7 0.71 0.194 0.984
Block size 8 6 32 21.3 1.04 21.7 0.82 0.340 0.988
Table 7: Selection of admissible designs, including stochastically curtailed designs with stopping permitted after every
four and eight patients, for scenario 1: (α, β, p0, p1) = (0.05, 0.15, 0.10, 0.30). For all designs, requisite type I error and
power is reached. Columns %Sp0 and %Sp1 show expected sample size as a proportion of Simon’s design under p = p0
and p = p1 respectively.
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Figure 8: Bias, RMSE for H0-optimal designs, scenario 1 (α, β, p0, p1) = (0.05, 0.15, 0.10, 0.30). Designs: (a, b) Simon’s
design; (c, d) Simon with go; (e, f) NSC.
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Figure 8: Bias, RMSE for H0-optimal designs, scenario 1 (α, β, p0, p1) = (0.05, 0.15, 0.10, 0.30), continued. Designs:
(g, h) SC; (i, j) m-stage.
Bias (absolute) RMSE
Bias adj. Bias subt. Naı¨ve MUE UMVUE Bias adj. Bias subt. Naı¨ve MUE UMVUE
Simon 0.01 0.01 0.03 0.03 0.00 0.10 0.10 0.10 0.11 0.10
SimonGO 0.01 0.01 0.03 0.05 0.00 0.15 0.15 0.14 0.15 0.15
NSC 0.01 0.01 0.04 0.03 0.00 0.16 0.17 0.16 0.16 0.17
SC 0.02 0.03 0.09 0.03 0.00 0.23 0.24 0.22 0.22 0.24
m-stage 0.03 0.02 0.09 0.02 0.00 0.23 0.24 0.23 0.23 0.25
Table 8: Maximum absolute bias and RMSE for various point estimators of H0-optimal designs, scenario 1:
(α, β, p0, p1) = (0.05, 0.15, 0.1, 0.3).
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Choosing thresholds
For a single-stage NSC design, the number of possible CP values (including zero and one) is
given by
(r + 1)(N − r) + 1,
which is a quadratic equation that reaches a maximum at r = (N − 1)/2. The number of
possible CPs increases linearly with N . A’Hern [1] states without proof that the final stopping
boundary for a single-stage trial with no curtailment will be approximately
r = N(p0 + [(zα/(zα + z1−β))× (p1 − p0)]). (1)
For a single-stage trial, N = 40 and design parameters (α, β, p0, p1) = (0.05, 0.20, 0.10, 0.30),
the approximate stopping boundary given by Equation (1) is r = 9.5967. Setting r equal to the
smallest integer greater than this, 10, such a trial would have 331 possible CP values, resulting
in 54,615 ordered pairs (θF , θE) such that θF < θE.
For a two-stage NSC design, the number of possible CP values is given by
(r1 + 1)(n1 − r1) + (r − r1)(N − r)− 1.
It is possible to employ constraints that further reduce the the number of possible ordered
pairs, using the following argument: If a trial using SC reaches its penultimate stage, i.e.
m = N − 1, without a decision being made, then the trial will result in a go decision if the
final participant responds and a no-go decision if the final participant does not respond. The
conditional power at this point, CP (p1)r,N−1, is equal to p1. Under SC, a trial stops for a no-go
decision if CP < θF . However, if the true response rate is great enough to warrant further
study, then the probability of a go decision at this point is p ≥ p1, and so the trial should never
be curtailed for a no-go decision at this point. As such, θF should be constrained such that
θF < p1. Introducing this constraint reduces the the number of possible ordered pairs (θF , θE)
in the above two-stage example to 12,084. Finally, for all admissible designs incorporating SC
across all scenarios, θE > 0.97. With this in mind, constraining the search to require θE > 0.95
reduces the number of ordered pairs to 7,809. This is comparable to the number of ordered
pairs that would be produced when searching over the uniform sequence {0, 0.01, ... 1}, which
is 5,050.
Admissible design search
The computational intensity of searching for admissible designs increases with the number of
possible trials, so it is of interest to use sensible constraints for the range of r. A’Hern states
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without proof that for a single-stage design without curtailment, the trial end stopping bound-
ary r lies in the interval [Np0, Np1] [1]; as such, the final stopping boundary for the proposed
designs is constrained to this interval. As an alternative, the boundaries for Wald’s sequential
probability ratio test may be used as constraints [2]; This is a design with no maximum sample
size N : the trial simply continues until a go or no-go decision can be made with the requi-
site level of certainty. Wald derives lower and upper stopping boundaries for the sequential
probability ratio test to be
SNOGO =
1
D
(
log
β
1− α +m log
1− p0
1− p1
)
SGO =
1
D
(
log
1− β
α
+m log
1− p0
1− p1
)
,
where
D = log
p1
p0
− log 1− p1
1− p0
after m participants. All admissible designs using the proposed designs all three scenarios
were obtained using A’Hern’s boundaries, and were also within the more strict boundaries of
Wald. We therefore recommend that Wald’s boundaries are used to constrain r, to reduce
computational intensity.
Wald’s sequential probability ratio test
Wald’s sequential probability ratio test, introduced directly above, results in a lower expected
sample size than many existing design types with the same choice of type I error and power
[2]. As such, it is worthwhile to compare how close the expected sample size of a given design
is to the expected sample size obtained using this test. Hence for each scenario, the expected
sample sizes of the H0- and H1-optimal admissible designs were compared to those of Wald.
For this design, the expected sample size under p = p0 is
E(N |p0) =
(1− α) log β
1−α + α log
1−β
α
p0 log
p1
p0
+ (1− p0) log 1−p11−p0
.
The expected sample size under p = p1 is
E(N |p1) =
β log β
1−α + 1− β log 1−βα
p1 log
p1
p0
+ (1− p1) log 1−p11−p0
.
Designs that are unfeasible in their uncurtailed form
The type I error and power of uncurtailed designs are not calculated prior to adding curtailment,
as a design that is feasible after SC may not be feasible before the incorporation of SC. For
example, take the design parameters (α, β, p0, p1) = (0.05, 0.2, 0.1, 0.4). The single-stage design
(N, r) = (21, 4) for (p0, p1) = (0.1, 0.4) has operating characteristics (α, β) = (0.052, 0.037)
(rounded to three d.p.), which is not feasible as α > 0.05. However, applying SC by using
the thresholds (θF , θE) = (0.31744, 0.9919024) results in the operating characteristics (α, β) =
(0.048, 0.141) (rounded to three d.p.), which is feasible and has E(N |p0) = 7.5, E(N |p1) = 7.6
(rounded to two d.p).
2
Expected loss by design
Heat maps of expected loss for the admissible designs of each design are shown in Figures 1,
2 and 3 for scenarios 1, 2 and 3 respectively. In each scenario, it can be seen that the novel
designs, particularly those that employ SC (SC and m-stage) have a lower expected loss in
general. These design types seem most superior in regions where N is weighted close to 0,
(that is, near the hypotenuse) and E(N |p0) is close to 0 (that is, where q0 ≈ 0).
Admissible designs, by design type (scenarios 2 and 3)
For completeness, the range of admissible designs for each compared design for scenarios 2 and
3 is shown in Figures 4 and 5.
Point estimators for multi-stage trials
The RMSE can be obtained using the bias and the variance of the estimate of the response rate.
With the exception of the UMVUE, the adjusted estimators for response rate have not been
described for multi-stage trials. The bias-subtracted and bias-adjusted estimators are described
in terms of the expected value of the response rate and its bias. The expected estimate of the
response rate, pˆ, can be obtained by taking the product of the observed response rate for each
possible terminal point and its probability given some true p, and summing across all possible
terminal points:
E(pˆ|p, r, a,n) =
m∑
g=1
ng∑
S=0
pˆ(Sng , ng)U(Sng , ng|p, r, a,n),
where r = r1, r2, . . . , rm and a = a1, a2, . . . , am are the vectors of stopping boundaries for go
and no-go decisions respectively at each stage, and n = n1, n2, . . . , nm is the vector of sample
size at each stage. The bias, variance and RMSE are as follows:
Bias(pˆ|p, r, a,n) = E(pˆ|p, r, a,n)− p
Var(pˆ|p, r, a,n) = E(pˆ2|p, r, a,n)− E(pˆ|p, r, a,n)2
RMSE(pˆ|p, r, a,n) =
√
Bias(pˆ|p, r, a,n)2 + Var(pˆ|p, r, a,n)
As stated in the main body of the paper, the na¨ıve estimator for p is simply pˆnaive = Sm/m.
The bias-subtracted estimator is then
pbias−sub = pˆnaive − Bias(pˆnaive|pˆnaive, r, a,n)
The bias-adjusted estimator is the numerical solution to
pbias−adj = pˆnaive − Bias(pˆnaive|pˆbias−adj, r, a,n)
Finally, the median unbiased estimator, pˆMUE is obtained by numerically searching for the
value of p that would make the p-value equal to 0.5:
p-val(Sm,m|pˆMUE) = 0.5,
where the p-value is computed as the sum of the probability of possible outcomes with a
larger value of the UMVUE. The estimates for all estimators are obtained using the R package
singlearm (https://github.com/mjg211/singlearm).
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Figure 1: Expected loss for each design type: (a) Simon’s design; (b) Simon with go; (c) NSC;
(d) SC; (e) m-stage, for scenario 1 (α, β, p0, p1) = (0.05, 0.15, 0.10, 0.30).
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Figure 2: Expected loss for each design type: (a) Simon’s design; (b) Simon with go; (c) NSC;
(d) SC; (e) m-stage, for scenario 2 (α, β, p0, p1) = (0.05, 0.20, 0.10, 0.30).
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Figure 3: Expected loss for each design type: (a) Simon’s design; (b) Simon with go; (c) NSC;
(d) SC; (e) m-stage, for scenario 3 (α, β, p0, p1) = (0.05, 0.20, 0.20, 0.40).
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Figure 4: Admissible designs for each design type: (a) Simon’s design; (b) Simon with go; (c)
NSC; (d) SC; (e) m-stage, for scenario 2 (α, β, p0, p1) = (0.05, 0.20, 0.10, 0.30).
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Figure 5: Admissible designs for each design type: (a) Simon’s design; (b) Simon with go; (c)
NSC; (d) SC; (e) m-stage, for scenario 3 (α, β, p0, p1) = (0.05, 0.20, 0.20, 0.40).
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